Suppr超能文献

发展中世界肿瘤学中的个性化医疗:改善的障碍与概念

Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve .

作者信息

Adeniji Adeoluwa Akeem, Dulal Soniya, Martin Mike G

机构信息

Oncology and Radiotherapy Department, Lagos University Teaching Hospital, Lagos, Nigeria.

National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu, Nepal.

出版信息

World J Oncol. 2021 Jun;12(2-3):50-60. doi: 10.14740/wjon1345. Epub 2021 May 14.

Abstract

Personalized medicine (PM) has revolutionized oncology management in high human development indexed countries. By interrogating both disease and host factors through a variety of tools, oncologists have been able to better target an individual's cancer, leading to improved outcomes. But both the tools used to define these variables, such as next generation sequencing, large immunohistochemical and fluorescence hybridization (FISH) panels, and the weapons employed against each target are extremely expensive. The expenses have to be measured as not only the direct cost to the patient but also the cost to the system to develop and deploy the necessary infrastructure to optimally use them. However, the concepts of predictive, timely prevention and PM have demonstrated improvement in patient's satisfaction and cost effectiveness. In this paper we will summarize the relevant barriers and challenges that limit the implementation of PM in the developing world with an emphasis on the challenges in Nigeria and Nepal.

摘要

个性化医疗(PM)已经彻底改变了高人类发展指数国家的肿瘤学管理模式。通过使用各种工具来探究疾病和宿主因素,肿瘤学家能够更好地针对个体的癌症进行治疗,从而改善治疗效果。但是,用于定义这些变量的工具,如下一代测序、大型免疫组织化学和荧光原位杂交(FISH)检测板,以及针对每个靶点所使用的手段都极其昂贵。这些费用不仅要衡量为患者带来的直接成本,还要衡量为开发和部署必要基础设施以优化使用这些工具而给系统带来的成本。然而,预测性、及时预防和个性化医疗的理念已经证明能够提高患者满意度并提升成本效益。在本文中,我们将总结限制个性化医疗在发展中世界实施的相关障碍和挑战,重点关注尼日利亚和尼泊尔所面临的挑战。

相似文献

2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Personalized oncology: recent advances and future challenges.个性化肿瘤学:最新进展与未来挑战。
Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19.
10
Sepsis Care Pathway 2019.2019年脓毒症护理路径
Qatar Med J. 2019 Nov 7;2019(2):4. doi: 10.5339/qmj.2019.qccc.4. eCollection 2019.

引用本文的文献

4
Liquid Biopsy in Solid Tumours: An Overview.实体肿瘤中的液体活检:概述
Cytopathology. 2025 Jul;36(4):296-302. doi: 10.1111/cyt.13485. Epub 2025 Apr 11.

本文引用的文献

3
FGFR inhibitors for advanced cholangiocarcinoma.用于晚期胆管癌的成纤维细胞生长因子受体(FGFR)抑制剂
Lancet Oncol. 2020 May;21(5):610-612. doi: 10.1016/S1470-2045(20)30152-2. Epub 2020 Mar 20.
9
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验